Headline
The latest stories from AHA Today.
Given the sustained increase in variants resistant to bamlanivimab alone, and availability of alternative authorized monoclonal antibodies, the U.S. government, in coordination with Eli Lilly, will stop the distribution of bamlanivimab alone starting today, the Department of Health and Human…
A new toolkit from AHA’s Institute for Diversity and Health Equity focuses on leveraging patient data to advance health equity. The first in a new series of health equity resources, the toolkit was released last week in concert with the Accelerating Health Equity Conference.
The AHA voiced support for the Resident Physician Shortage Reduction Act of 2021 (S. 834), legislation that would add 14,000 Medicare-funded residency positions to alleviate physician shortages that threaten patients’ access to care.
Join the AHA March 30 at 12 p.m. ET to hear how Atrium Health and American Airlines came together to “get shots in arms” through mass vaccination events in Charlotte, N.C. Webinar speakers will discuss the planning, partnerships and support required to hold these events.
A new analysis prepared by Kaufman, Hall & Associates LLC and released by the AHA shows that even under the most optimistic scenario, including a smooth vaccine roll-out and reduced COVID-19 hospitalizations, 39% of hospitals would operate in the red in 2021, a marked increase over pre-pandemic…
The National Resident Matching Program matched a record 36,179 medical school seniors and graduates to U.S. residency positions, 2.6% more than last year. Applicants include students and graduates of U.S. and international medical schools.
The AHA Center for Health Innovation invites hospitals and health systems to participate in its second Hospital Community Collaborative, which will focus on COVID-19-related community needs.
The Food and Drug Administration authorized for emergency use an armband device that screens people without COVID-19 symptoms for certain potential SARS-CoV-2 biomarkers, such as excessive blood clotting.
AstraZeneca said its AZD1222 COVID-19 vaccine candidate is safe and effective, based on data culled from a phase 3 clinical trial of 32,449 U.S. patients.
The House of Representatives voted 246-175 to approve H.R. 1868, a bill that, among other health care provisions, would eliminate the 2% across-the-board cut to all Medicare payments, known as sequestration, until the end of 2021.